PatientsVille.com Logo


Fortecortin Medical Research Studies

Up-to-date List of Fortecortin Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Fortecortin Medical Research Studies

Rank Status Study
1 Recruiting Dexamethasone Intravitreal Implant After Vitrectomy For Epiretinal Membrane
Conditions: Epiretinal Membrane;   Macular Edema
Intervention: Drug: Dexamethasone Intravtireal Implant
Outcome Measures: Changes in best corrected visual acuity;   Incidence of persistent macular edema on Central OCT thickness in treatment (PPV + MP + DEX) versus non-treatment (PPV + MP) groups
2 Recruiting Recombinant Human Thrombopoietin (rhTPO) Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)
Conditions: Purpura;   Idiopathic Thrombocytopenic Purpura
Interventions: Drug: recombinant human thrombopoietin (rhTPO); dexamethasone;   Drug: Dexamethasone
Outcome Measures: Evaluation of platelet response;   Evaluation of platelet response (R)
3 Recruiting Trial of Switching Between Intravitreal Bevacizumab (Avastin®)& Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema
Conditions: Diabetes;   Diabetic Macular Oedema;   Diabetic Macular Edema;   Diabetic Retinopathy
Interventions: Drug: Avastin (Bevacizumab);   Drug: Ozurdex (dexamethasone)
Outcome Measures: Proportion of eyes that have central macular thickness <300 microns 6 months after switching;   Mean change in central macular thickness (CMT) as measured by OCT.
4 Recruiting Dexamethasone for the Treatment of Established Postoperative Nausea and Vomiting
Conditions: Postoperative Nausea and Vomiting;   Vomiting
Interventions: Drug: Injection of Placebo (saline 0.9%);   Drug: Dexamethasone 3 mg intravenously;   Drug: Dexamethasone 6 mg;   Drug: Dexamethasone 12 mg
Outcome Measures: Treatment efficacy of Dexamethasone for established PONV;   Evaluation of the potential adverse effect profile of dexamethasone
5 Recruiting An Investigation of Dexamethasone With Different Doses in the Management of Immune Thrombocytopenia (ITP)
Condition: Immune Thrombocytopenia
Intervention: Drug: Dexamethasone
Outcome Measures: Proposed criteria for assessing early response to ITP treatments;   Safety
6 Recruiting A Comparison of Ropivacaine Alone Versus Combination of Dexamethasone and Clonidine for Block
Condition: Upper Extremity Fracture
Interventions: Drug: Ropivacaine;   Drug: Ropivacaine and dexamethasone;   Drug: Ropivacaine, dexamethasone, clonidine;   Drug: Ropivacaine and clonidine
Outcome Measures: Duration of the supraclavicular block;   Postoperative analgesia
7 Recruiting Trial Comparing Duration of Analgesia After Popliteal Fossa Sciatiac Nerve Block With Ropivacaine 0.5% When Combined With Placebo, Dexamethasone 4mg or Dexamethasone 8 mg
Condition: Pain, Sciatic Block
Interventions: Drug: Placebo;   Drug: Dexamethasone 4 mg;   Drug: Dexamethasone 8 mg
Outcome Measures: Duration of analgesia;   Total pain medication;   Pain scores
8 Recruiting High-dose Dexamethasone Combining Thalidomide Versus Dexamethasone Mono-therapy for Management of Newly-diagnosed ITP
Condition: Immune Thrombocytopenia
Interventions: Drug: Dexamethasone;   Drug: Thalidomide
Outcome Measure: Evaluation of platelet response
9 Recruiting Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma
Condition: Myeloma
Interventions: Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: All-Trans Retinoic Acid (ATRA)
Outcome Measures: Maximum Tolerated Dose (MTD) of Lenalidomide/Dexamethasone and All-Trans Retinoic Acid (ATRA);   Objective Response
10 Recruiting Analgesic Effect of Intra-articular Dexamethasone and Dexamethasone Added to Bupivacaine in Interscalene Brachial Plexus
Condition: Postoperative Pain
Interventions: Procedure: intraarticular dexamethasone;   Procedure: interscalene dexamethasone
Outcome Measures: analgesic consumption;   visual analog scale
11 Unknown  Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone Treatment
Condition: Cisplatin Ototoxicity
Intervention: Drug: Dexamethasone Phosphate
Outcome Measure: Examine possible protective effect of IT dexamethasone on cisplatin-induced hearing loss. Hearing assessment would include:pure tone, speech and impedance audiometry, and Distortion Product Otoacoustic Emissions (DPOAEs) testing.
12 Recruiting Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
Conditions: Cognitive/Functional Effects;   Fatigue;   Neurotoxicity;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Therapy-related Toxicity;   Waldenström Macroglobulinemia
Interventions: Drug: temsirolimus;   Biological: rituximab;   Drug: bortezomib;   Drug: dexamethasone;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
Outcome Measures: MTD and recommended phase II dose of temsirolimus in combination with bortezomib, rituximab, and dexamethasone (Phase I);   Progression-free survival (PFS) of patients treated with temsirolimus in combination with bortezomib, rituximab, and dexamethasone (Phase II);   Response rates and duration of response (Phase II);   Time to disease progression (Phase II);   Duration of response (Phase II);   Time to next therapy (Phase II);   Overall survival of patients (Phase II);   Change in the Functional Assessment of Cancer Therapy (FACT)-Fatigue Trial Outcome Index (TOI) score between the two treatment arms
13 Recruiting Multicentre Randomised Clinical Trial Comparing Fixed vs Pro re Nata (PRN) Dosing of 700 μg Dexamethasone
Condition: Diabetic Macular Edema
Intervention: Device: Ozurdex
Outcome Measures: The difference between arms in the change from baseline in best corrected visual acuity at 12 months;   Difference between arms in change from baseline in each domain and composite scores of the National Eye Institute Visual function questionnaire (VFQ-25).;   Difference between arms in change in central subfield thickness.;   Proportion of patients with ocular and systemic serious adverse events
14 Recruiting Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema
Conditions: Macular Edema, Cystoid;   Vision Disorders;   Diabetic Macular Edema;   Cystoid Macular Edema Following Cataract Surgery;   Cataract
Interventions: Drug: Dexamethasone Drug delivery system (Ozurdex);   Procedure: Cataract surgery
Outcome Measures: change in the central macular thickness;   Change in the visual acuity
15 Not yet recruiting A Pilot Study of the Effectiveness of Intra-operative Ozurdex® in Vitrectomy Surgery for Epiretinal Membranes
Conditions: Epiretinal Membrane;   Macular Edema
Intervention: Drug: Ozurdex
Outcome Measures: Best corrected visual acuity;   Best corrected visual acuity at 1,4 and 6 months;   Retinal thickness and volume;   Intraocular pressure (IOP);   Cataract progression (if applicable)
16 Recruiting Comparison of Analgesic Consumption Between Perioperative ıv Dexamethasone and Added to Femoral Block
Condition: Postoperative Pain
Interventions: Drug: iv dexamethasone;   Drug: femoral dexamethasone;   Drug: serum physiologic
Outcome Measures: visual analog scale;   analgesic consumption
17 Recruiting Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Refractory Multiple Myeloma
Interventions: Drug: pomalidomide;   Drug: bortezomib;   Drug: dexamethasone;   Other: laboratory biomarker analysis;   Other: gene expression analysis
Outcome Measures: Maximum tolerated dose (MTD) of bortezomib in combination with pomalidomide and dexamethasone out to 2.5 years.;   Hematologic response rate (PR, VGPR, or CR) of pomalidomide, bortezomib and dexamethasone in patients with relapsed or refractory myeloma out to 2.5 years;   Time to progression.;   Toxicity of pomalidomide, bortezomib and dexamethasone in this patient population.
18 Recruiting Study of Oprozomib and Dexamethasone, in Combination With Lenalidomide or Oral Cyclophosphamide in Patients With Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Oprozomib;   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Cyclophosphamide
Outcome Measures: To establish the maximum tolerated dose (MTD) of oprozomib and dexamethasone administered in combination with lenalidomide or oral cyclophosphamide;   To evaluate the safety and tolerability of oprozomib and dexamethasone administered in combination with lenalidomide or oral cyclophosphamide;   To estimate the overall response rate (ORR);   To estimate the complete response rate (CRR);   To evaluate population pharmacokinetic (PK) parameter estimates of oprozomib and variability in these estimates when administered in combination with lenalidomide and dexamethasone, or oral cyclophosphamide and dexamethasone;   To estimate the duration of response (DOR);   To estimate progression-free survival (PFS)
19 Recruiting Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Biological: Elotuzumab;   Drug: Bortezomib;   Drug: Dexamethasone
Outcome Measures: Progression-free survival (PFS) - Time from randomization to date of first tumor progression or death due to any cause;   PFS hazard ration in the subgroup of subjects with at least one FcγRIIIa V allele;   Difference in response rates between treatment arms in the overall population;   Estimate the difference in response rates between arms in the subgroup of subjects with at least one FcγRIIIa V allele
20 Not yet recruiting Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma
Conditions: Macular Edema;   Cystoid Macular Edema;   Uveal Melanoma;   Radiation Maculopathy;   Radiation Retinopathy
Interventions: Drug: Ozurdex;   Drug: Bevacizumab
Outcome Measures: Proportion of eyes showing >=2 lines of improvement in best-corrected visual acuity;   Change in central subfield retinal thickness;   Development of glaucoma;   Development of cataract;   Development of retinal detachment;   Development of vitreous hemorrhage

These studies may lead to new treatments and are adding insight into Fortecortin etiology and treatment.

A major focus of Fortecortin research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Fortecortin